Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Epinastine Nasal Spray Formulations vs Azelastine for Allergic Rhinitis
NCT01382654Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Sep 2006
- Primary completion
- Oct 2006
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial of epinastine in allergic rhinitis (AR) (5 arms), sponsored by Merck & Co. Primary endpoint: Overall preference rank at the completion of the study using the Overall Nasal Spray Evaluation Questionnaire (NSEQ) at 2 days. Started Sep 2006; status: completed.
02
Drugs
epinastine
03
Conditions
allergic rhinitis (AR)
Beyond the preview
Go deeper on NCT01382654.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01382654.